权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Functionalized Enzyme Treatments for Dual-Targeting of Inflammation in Spinal Cord Injury

功能化酶治疗脊髓损伤炎症的双重靶向

基本信息

批准号：
10284992
负责人：
Benjamin George Keselowsky
金额：
$ 41万
依托单位：
UNIVERSITY OF FLORIDA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2024-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10284992
关键词：
Acute Anti-Inflammatory Agents Astrocytes Autoimmune Binding Binding Proteins Blood Blood Circulation Carbohydrates Cause of Death Cell Death Cells Chronic Cicatrix Clinical Complex Cues Deposition Dioxygenases Down-Regulation Engineering Enzymes Extracellular Matrix FDA approved Feedback Formulation Galectin 3 Glycosaminoglycans Goals Growth Homeostasis Hour Human body Hydrogels Immune Immune response Immunomodulators Individual Infiltration Inflammation Inflammatory Inflammatory Response Injectable Injections Injury Intravenous Kynurenine Lesion Leukocytes Liver Methylprednisolone Microglia Modification Mus Muscle Natural regeneration Nerve Neuraxis Neuroglia Pathology Pathway interactions Pharmaceutical Preparations Phenotype Polyethylene Glycols Polysaccharides Process Production Prognosis Property Protein Engineering Proteins Psoriasis Recombinant Proteins Recombinants Recovery of Function Regimen Reperfusion Injury Research Site Skin Spinal Cord Spinal Cord Lesions Spinal cord injury Spinal cord injury patients Steroids Target Populations Therapeutic Therapeutic Effect Time Tissues Translations Trauma Traumatic CNS injury Tryptophan Tryptophan 2,3 Dioxygenase Up-Regulation Work axon regeneration central nervous system injury cost cytokine design disability effective therapy efficacy testing enzyme therapy glial activation healing hydrogel scaffold immunoregulation improved indoleamine inhibitor/antagonist innovation intravenous administration macrophage monocyte neuroinflammation neutrophil novel novel strategies novel therapeutics pre-clinical research public health relevance regenerative regenerative cell relating to nervous system repaired response scaffold standard of care systemic inflammatory response tissue repair wound healing

项目摘要

PROJECT SUMMARY Unlike other tissues, such as skin and muscle that are capable of complete tissue remodeling, the central nervous system (CNS) lacks the ability to properly heal after injury. Instead, CNS wound repair is marked by sustained glial reactivity and scar tissue deposition, all of which are exacerbated by inflammation. Therapeutic application of the anti-inflammatory methylprednisolone is the only current treatment option for spinal cord injury (SCI), however, it only has acute efficacy and does not resolve tissue remodeling or scarring. This project proposes to investigate idoleamine 2,3-dioxygenase (IDO) as a novel immunomodulatory therapeutic for SCI. IDO is attractive for its dual targeting ability not only to downregulate pro-inflammatory responses but also to promote pro-regenerative cell phenotypes, effectively restoring the imbalance of inflammatory processes after CNS injury. The guiding hypothesis of this research is that IDO will have dual efficacy in immunomodulation of acute systemic inflammation and mitigation of chronic resident cell activation and scarring in the spinal cord. Moreover, the project will investigate two innovative, functionalized forms of IDO for directed targeting of systemic and localized immunomodulation in SCI. First, IDO modified with polyethylene glycol (PEG) will be used for systemic intravenous administration immediately after SCI. PEG improves protein stability in blood and prolongs circulation time, making it an ideal candidate for systemic delivery. PEG-IDO will target circulating leukocytes to modulate early stage inflammation after injury. Secondly, IDO fused with galectin- 3 (Gal3), a glycan binding protein to increase local retention at a tissue target site, will be delivered one week after injury to evaluate effects on resident cell reactivity, reparative immune cell presence, and tissue scarring. The rationale for this design is to better harness IDO’s ability to promote reparative mechanisms in immune cells and glia that are locally present around the lesion site. Co-administration of IDO-Gal3 with key compounds that direct production of neuroprotective metabolites by resident glia (i.e., KMO inhibitors) will further enhance therapeutic effects of localized IDO. Together, this combination will be delivered within a novel, pro-regenerative decellularized neural scaffold to synergistically mitigate neuroinflammation. Overall, the dual immunomodulation potential of IDO provides a new perspective for anti-inflammatory drug administration for CNS injury. The proposed work will demonstrate merit for the individual novel approaches with PEG-IDO and IDO-Gal3 for cell-specific targeting. The long-term goal is to use this mechanistic understanding as a first step in research efforts to develop more effective combination strategies for CNS repair.

项目总结